PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Description:

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.

Highlights

Key Questions Answered

- Even with more than 20 AEDs on the market, there are still ~20% refractory patients. Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the epilepsy market?
- Several brands of AEDs are due for patent expiry. How will the patent expiries impact the epilepsy therapeutics market?
- The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?
- What governmental changes are likely to change the epilepsy treatment landscape in the markets researched? Which is the biggest growth market globally?

Key Findings

- New market entrants particularly Fycompa, Trobalt/Potiga and brivaracetam will increase competitiveness and cannibalize sales of existing AEDs.
- Drivers for market growth will include the introduction of the newer epilepsy drugs into the Asian market, particularly in Japan.
- Government cost-cutting measures will negatively impact epilepsy drug market in the EU

Scope

- Overview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized epilepsy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including ion channel modulators, GABA modulators, glutamate receptor antagonists, inflammation inhibitors, synaptic and gap junction blockers, sigma receptor agonists and acetylcholine modulators.
- Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global epilepsy therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Related Reports
3 Disease Overview
3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Prognosis
3.2.4 Quality of Life
4 Epidemiology
4.1 Risk Factors and Comorbidities
4.1.1 Risk factors in newborns often include brain malformations and lack of oxygen
4.1.2 Genetic factors and head trauma are risk factors in adults and children
4.1.3 Common seizure triggers include lack of sleep, stress, and photosensitivity
4.1.4 Epilepsy comorbidities in adults and children include pain disorders
4.1.5 Anxiety and depression are major epilepsy comorbidities
4.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries
4.2 Global Trends
4.2.1 United States
4.2.2 5EU Markets (France, Germany, Italy, Spain, and UK)
4.2.3 Asia
4.3 Forecast Methodology
4.3.1 Sources Used
4.3.2 Forecast Assumptions and Methods
4.3.3 Sources Not Used
4.4 Epidemiologic Forecast
4.4.1 Total Active Prevalent Cases of Epilepsy
4.4.2 Total Lifetime Prevalent Cases of Epilepsy
4.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy
4.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy
4.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy
4.5 Discussion
4.5.1 Conclusion on Epidemiological Trends
4.5.2 Limitations of the Analysis
4.5.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis
5.2 Treatment Guidelines
5.3 Clinical Practice
5.4 US
5.4.1 Diagnosis
5.4.2 Clinical Practice
5.5 UK
5.5.1 Diagnosis
5.5.2 Clinical Practice
5.6 France
5.6.1 Diagnosis
5.6.2 Clinical Practice
5.7 Germany
5.7.1 Diagnosis
5.7.2 Clinical Practice
5.8 Spain
5.8.1 Diagnosis
5.8.2 Clinical Practice
5.9 Italy
5.9.1 Diagnosis
5.9.2 Clinical Practice
5.10 Japan
5.10.1 Diagnosis
5.10.2 Clinical Practice
5.11 India
5.11.1 Diagnosis
5.11.2 Clinical Practice
5.12 China
5.12.1 Diagnosis
5.12.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Major Brands
6.3.1 Keppra (levetiracetam)
6.3.2 Lamictal (lamotrigine)
6.3.3 Lyrica (pregabalin)
6.3.4 Vimpat (lacosamide)
6.3.5 Zonegran (zonisamide)
6.3.6 Banzel/Inovelon (rufinamide)
6.3.7 Trobalt/Potiga (retigabine/ezogabine)
6.3.8 Zebinix/Aptiom (eslicarbazepine acetate)
6.3.9 Fycompa (perampanel)
6.3.10 Older-Generation AEDs
7 Opportunity and Unmet Need
7.1 Overview
7.2 Unmet Needs
7.2.1 Refractory Epilepsy
7.2.2 Safety/Side Effect Profiles
7.2.3 Curative/Disease-Modifying Agents
7.2.4 Predictive Tools and Need for More Directed Treatments
7.2.5 Improved Preclinical Models and Clinical Trial Paradigms
7.2.6 Treatment Gap
7.3 Unmet Needs Gap Analysis
7.4 Opportunities
7.4.1 Disease-Modifying Agents
7.4.2 Improved Preclinical Models and Clinical Trial Paradigms
7.4.3 Treatment Gap
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Country
8.3 Clinical Trials by Phase and Trial Status
8.4 Strategic Pipeline Assessment
8.5 Pipeline by Phases of Development
8.5.1 Phase III Pipeline
8.5.2 Phase III Pipeline - Reformulations/New Delivery Systems
8.5.3 Phase IIIb Pipeline
8.5.4 Phase II Pipeline
8.5.5 Phase I Pipeline
8.5.6 Preclinical Pipeline
8.5.7 Discovery Pipeline
8.6 Pipeline by Mechanism of Action
8.7 Promising Drugs in Clinical Development
8.7.1 Brivaracetam
8.7.2 Ganaxolone
8.7.3 VX-765
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 UCB
9.3.2 Eisai
9.3.3 Pfizer
9.3.4 GlaxoSmithKline
9.3.5 Novartis
9.3.6 Abbott
9.3.7 Dainippon Sumitomo Pharma
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 United States
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 France
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Germany
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Italy
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
10.6 Spain
10.6.1 Forecast
10.6.2 Key Events
10.6.3 Drivers and Barriers
10.7 United Kingdom
10.7.1 Forecast
10.7.2 Key Events
10.7.3 Drivers and Barriers
10.8 Japan
10.8.1 Forecast
10.8.2 Key Events
10.8.3 Drivers and Barriers
10.9 India
10.9.1 Forecast
10.9.2 Key Events
10.9.3 Drivers and Barriers
10.10 China
10.10.1 Forecast
10.10.2 Key Events
10.10.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Prevalent Epilepsy Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class Based on MOA
11.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Physicians and Specialists Included in this Study
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Authors
11.7.2 Epidemiologist
11.7.3 Global Head of Healthcare
11.8 About Us
11.9 Disclaimer

1.1 List of Tables
Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
Table 2: Classification of Seizures
Table 3: Etiology of Epilepsy According to Age
Table 4: Etiology of Partial Seizures
Table 5: Etiology of Generalized Seizures
Table 6: Some of the Genes Involved in Epilepsy
Table 7: Nine Markets, Sources for Prevalent Cases of Epilepsy Data
Table 8: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Table 9: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Table 10: Summary of Diagnostic Tools for Epilepsy
Table 11: Treatment Guidelines for Epilepsy
Table 12: AED Options by Seizure Type
Table 13: Top Three AEDs Prescribed for Epilepsy by Market
Table 14: Types of Epilepsy Surgery
Table 15: US, Epilepsy Patient Referrals to Neurologist
Table 16: US, Most-Prescribed First-Line and Second-Line AEDs
Table 17: UK, Epilepsy Patient Referrals to Neurologist
Table 18: UK, Most-Prescribed First-Line and Second-Line AEDs
Table 19: France, Epilepsy Patient Referrals to Neurologist
Table 20: France, Most-Prescribed First-Line and Second-Line AEDs
Table 21: Germany, Epilepsy Patient Referrals to Neurologist
Table 22: Germany, Most-Prescribed First-Line and Second-Line AEDs
Table 23: Spain, Epilepsy Patient Referrals to Neurologist
Table 24: Spain, Most-Prescribed First-Line and Second-Line AEDs
Table 25: Italy, Epilepsy Patient Referrals to Neurologist
Table 26: Italy, Most-Prescribed 1st-line and 2nd-line AEDs
Table 27: Japan, Epilepsy Patient Referrals to Neurologist
Table 28: Japan, Most-Prescribed 1st-line and 2nd-line AEDs
Table 29: India, Epilepsy Patient Referrals to Neurologist
Table 30: India, Most-Prescribed 1st-line and 2nd-line AEDs
Table 31: China, Epilepsy Patient Referrals to Neurologist
Table 32: China, Most-Prescribed First-Line and Second-Line AEDs
Table 33: Leading Treatments for Epilepsy, 2012
Table 34: Product Profile - Keppra
Table 35: Keppra SWOT Analysis, 2012
Table 36: Global Sales Forecasts ($m) for Keppra (levetiracetam), 2012-2022
Table 37: Product Profile - Lamictal
Table 38: Lamictal SWOT Analysis, 2012
Table 39: Global Sales Forecasts ($m) for Lamictal (lamotrigine), 2012-2022
Table 40: Product Profile - Lyrica
Table 41: Lyrica SWOT Analysis, 2012
Table 42: Global Sales Forecasts ($m) for Lyrica (pregabalin), 2012-2022
Table 43: Product Profile - Vimpat
Table 44: Vimpat SWOT Analysis, 2012
Table 45: Global Sales Forecasts ($m) for Vimpat (lacosamide), 2012-2022
Table 46: Product Profile - Zonegran
Table 47: Zonegran SWOT Analysis, 2012
Table 48: Global Sales Forecasts ($m) for Zonegran (zonisamide), 2012-2022
Table 49: Product Profile - Banzel/Inovelon
Table 50: Banzel/Inovelon SWOT Analysis, 2012
Table 51: Global Sales Forecasts ($m) for Banzel/Inovelon (rufinamide), 2012-2022
Table 52: Product Profile - Trobalt/Potiga
Table 53: Trobalt/Potiga SWOT Analysis, 2012
Table 54: Global Sales Forecasts ($m) for Trobalt/Potiga (retigabine/ezogabine), 2012-2022
Table 55: Product Profile - Zebinix/Aptiom
Table 56: Zebinix/Aptiom SWOT Analysis, 2012
Table 57: Global Sales Forecasts ($m) for Zebinix/Aptiom (eslicarbazolepine acetate), 2012-2022
Table 58: Product Profile - Fycompa
Table 59: Fycompa SWOT Analysis, 2012
Table 60: Global Sales Forecasts ($m) for Fycompa (perampanel), 2012-2022
Table 61: Summary of Minor Drug Classes, 2012
Table 62: Overall Unmet Needs - Current Level of Attainment
Table 63: Clinical Unmet Needs - Gap Analysis, 2012
Table 64: Epilepsy - Clinical Trials by Phase and Status, 2012
Table 65: Epilepsy - Phase III Pipeline, 2012
Table 66: Epilepsy - Phase III Pipeline (Reformulations), 2012
Table 67: Epilepsy - Phase IIb Pipeline, 2012
Table 68: Epilepsy - Phase II Pipeline, 2012
Table 69: Epilepsy - Phase I Pipeline, 2012
Table 70: Epilepsy - Preclinical Pipeline, 2012
Table 71: Epilepsy - Discovery Pipeline, 2012
Table 72: Comparison of MOA of Drugs in Development for Epilepsy, 2012
Table 73: Epilepsy - Promising Drugs in Clinical Development
Table 74: Product Profile - Brivaracetam
Table 75: Brivaracetam SWOT Analysis, 2012
Table 76: Global Sales Forecasts ($m) for Brivaracetam, 2012-2022
Table 77: Product Profile - Ganaxolone
Table 78: Ganaxolone SWOT Analysis, 2012
Table 79: Global Sales Forecasts ($m) for Ganaxolone, 2012-2022
Table 80: Product Profile - VX-765
Table 81: VX-765 SWOT Analysis, 2012
Table 82: Global Sales Forecasts ($m) for VX-765, 2012-2022
Table 83: Key Companies in the Epilepsy Market, 2012
Table 84: UCB's Epilepsy Portfolio Assessment, 2012
Table 85: UCB SWOT Analysis, 2012
Table 86: Eisai's Epilepsy Portfolio Assessment, 2012
Table 87: Eisai SWOT Analysis, 2012
Table 88: Pfizer's Epilepsy Portfolio Assessment, 2012
Table 89: Pfizer SWOT Analysis, 2012
Table 90: GlaxoSmithKline's Epilepsy Portfolio Assessment, 2012
Table 91: GlaxoSmithKline SWOT Analysis, 2012
Table 92: Novartis' Epilepsy Portfolio Assessment, 2012
Table 93: Novartis SWOT Analysis, 2012
Table 94: Abbott's Epilepsy Portfolio Assessment, 2012
Table 95: Abbott SWOT Analysis, 2012
Table 96: Dainippon Sumitomo's Epilepsy Portfolio Assessment, 2012
Table 97: Dainippon Sumitomo SWOT Analysis, 2012
Table 98: Global Sales Forecasts ($m) for Epilepsy, 2012-2022
Table 99: Global Epilepsy Market - Drivers and Barriers, 2012-2022
Table 100: Sales Forecasts ($m) for Epilepsy in the United States, 2012-2022
Table 101: Key Events Impacting Sales for Epilepsy in the United States, 2012-2022
Table 102: Epilepsy Market in the US - Drivers and Barriers, 2012-2022
Table 103: Sales Forecasts ($m) for Epilepsy in France, 2012-2022
Table 104: Key Events Impacting Sales for Epilepsy in France, 2012-2022
Table 105: Epilepsy Market in France - Drivers and Barriers, 2012-2022
Table 106: Sales Forecasts ($m) for Epilepsy in Germany, 2012-2022
Table 107: Key Events Impacting Sales for Epilepsy in Germany, 2012-2022
Table 108: Epilepsy Market in Germany - Drivers and Barriers, 2012-2022
Table 109: Sales Forecasts ($m) for Epilepsy in Italy, 2012-2022
Table 110: Key Events Impacting Sales for Epilepsy in Italy, 2012-2022
Table 111: Epilepsy Market in Italy - Drivers and Barriers, 2012-2022
Table 112: Sales Forecasts ($m) for Epilepsy in Spain, 2012-2022
Table 113: Key Events Impacting Sales for Epilepsy in Spain, 2012-2022
Table 114: Epilepsy Market in Spain - Drivers and Barriers, 2012-2022
Table 115: Sales Forecasts ($m) for Epilepsy in the United Kingdom, 2012-2022
Table 116: Key Events Impacting Sales for Epilepsy in the United Kingdom, 2012-2022
Table 117: Epilepsy Market in the UK - Drivers and Barriers, 2012-2022
Table 118: Sales Forecasts ($m) for Epilepsy in Japan, 2012-2022
Table 119: Key Events Impacting Sales for Epilepsy in Japan, 2012-2022
Table 120: Sales Forecasts ($m) for Epilepsy in China, 2012-2022
Table 121: Key Events Impacting Sales for Epilepsy in China, 2012-2022
Table 122: Epilepsy Market in China - Drivers and Barriers, 2012-2022
Table 123: Key Launch Dates
Table 124: Key Patent Expiries and Market Exclusivity Expiries
Table 125: Physicians Surveyed, by Country

1.2 List of Figures
Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 2: Mechanisms of Action of AEDs at the Synapse
Figure 3: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Figure 4: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Figure 5: Nine Markets, Age-Specific Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, 2012
Figure 6: Nine Markets, Gender-Specific Total Active Prevalent Cases of Epilepsy, All Ages, 2012
Figure 7: Nine Markets, Seizure-Specific Proportions of Epilepsy, All Ages, Male and Female, 2012
Figure 8: AED Selection Based on Comorbidity
Figure 9: Epilepsy Therapeutics - Clinical Trials by Country, 2012
Figure 10: Epilepsy - Pipeline by MOA, 2012
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Epilepsy, 2012-2022
Figure 12: Company Portfolio Gap Analysis in Epilepsy, 2012-2022
Figure 13: Global Sales for Epilepsy by Region, 2012-2022
Figure 14: Sales for Epilepsy in the United States by Drug Class, 2012-2022
Figure 15: Sales for Epilepsy in France by Drug Class, 2012-2022
Figure 16: Sales for Epilepsy in Germany by Drug Class, 2012-2022
Figure 17: Sales for Epilepsy in Italy by Drug Class, 2012-2022
Figure 18: Sales for Epilepsy in Spain by Drug Class, 2012-2022
Figure 19: Sales for Epilepsy in the United Kingdom by Drug Class, 2012-2022
Figure 20: Sales for Epilepsy in Japan by Drug Class, 2012-2022
Figure 21: Sales for Epilepsy in India by Drug Class, 2012-2022
Figure 22: Sales for Epilepsy in China by Drug Class, 2012-2022

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2977484/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
Web Address: http://www.researchandmarkets.com/reports/2977484/
Office Code: SCH3X2NY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Product Options</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User:</td>
<td>$10995</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td>$21990</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td>$32985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof

First Name: ___________________________ Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World